Advertisement
FATE vs PMCB
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and PMCB is a Hold.
FATE in -7.73% downward trend, falling for three consecutive days on October 16, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where FATE declined for three days, in 304 of 337 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 78 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 45 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
FATE moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for FATE entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FATE's RSI Oscillator exited the oversold zone, 28 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +15.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in 215 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.609) is normal, around the industry mean (3.009). P/E Ratio (-1.962) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PMCB's Indicator enters downward trend
The Aroon Indicator for PMCB entered a downward trend on September 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 266 similar instances where the Aroon Indicator formed such a pattern. In 238 of the 266 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMCB as a result. In 103 of 121 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PMCB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 45 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
PMCB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.132) is normal, around the industry mean (3.009). P/E Ratio (-0.165) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. PMCB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMCB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FATE | PMCB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 87 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 43 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | 90 | |
P/E GROWTH RATING 1..100 | 18 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PMCB's Valuation (43) in the null industry is in the same range as FATE (51) in the Biotechnology industry. This means that PMCB’s stock grew similarly to FATE’s over the last 12 months.
PMCB's Profit vs Risk Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that PMCB’s stock grew similarly to FATE’s over the last 12 months.
PMCB's SMR Rating (98) in the null industry is in the same range as FATE (98) in the Biotechnology industry. This means that PMCB’s stock grew similarly to FATE’s over the last 12 months.
FATE's Price Growth Rating (62) in the Biotechnology industry is in the same range as PMCB (90) in the null industry. This means that FATE’s stock grew similarly to PMCB’s over the last 12 months.
FATE's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for PMCB (97) in the null industry. This means that FATE’s stock grew significantly faster than PMCB’s over the last 12 months.
| FATE | PMCB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 77% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 78% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Advances ODDS (%) | 1 day ago 87% | N/A |
| Declines ODDS (%) | 5 days ago 90% | 2 days ago 85% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while PMCB’s FA Score has 0 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- PMCB’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while PMCB’s TA Score has 3 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 5 bearish.
- PMCB’s TA Score: 3 bullish, 4 bearish.
Price Growth
FATE (@Biotechnology) experienced а +3.00% price change this week, while PMCB (@Biotechnology) price change was -3.85% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
Reported Earning Dates
FATE is expected to report earnings on Nov 12, 2026.
PMCB is expected to report earnings on Dec 16, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement